各位老师和同学：
大家好，2026年7月2日（星期四），威廉体育williamhill邀请了Imperial College London的Edward Tate教授到访公司并进行“Chemical Biology for Drug Discovery”的讲座，欢迎大家参加！
嘉 宾：Ed Tate, Ph.D.
嘉宾单位：Imperial College London
主 题：Chemical Biology for Drug Discovery
时 间：2026年7月2日（星期四）16:00 - 17:30
地 点：C105
邀请人：彭涛
讲座摘要：
The Tate lab develops novel chemical biology approaches to enable drug discovery against post-translational modification (PTM) pathways and intractable drug targets, including chemical proteomic target identification, screening technologies, and chemical probe discovery for protein-protein interactions and enzymes modulating PTMs. Recent highlights include the development of new strategies to induce targeted protein degradation (TPD), the first cell-active activity-based probes (ABPs) for deubiquitinases (DUBs), new tools for analysis and discovery of pathogenic secreted protease activities, and the first comprehensive maps of specific classes of PTMs through chemical proteomics. Our research in the field of protein lipidation led to several drug discovery and target validation campaigns, spanning antimalarial and antiviral research to oncology. We are also interested in new modalities including targeted protein degradation and antibody-drug conjugates (ADCs), and translation of technologies and drug candidates through biotech spinouts. These include Myricx Bio (https://myricxbio.com/), building on our discovery of ultrapotent (low/sub picomolar) protein lipidation inhibitors as a unique class of next generation payloads for antibody-drug conjugates (ADCs), and Siftr Bio (https://siftr.bio/), leveraging our platforms for ABP discovery and their application in patient-derived tissues.
嘉宾简介：
Prof. Edward Tate holds the GSK Chair in Chemical Biology at Imperial College London, and he is a Group Leader at the Francis Crick Institute. Following his PhD (2000) with Steve Ley in Cambridge and postdoctoral research in Paris as an 1851 Fellow and Howard Trust Fellow, he was awarded a BBSRC David Phillips Fellowship in 2006 to start his group at Imperial College. He sits on the advisory boards of several international research institutes and biotechs, and develops new drug discovery technologies with companies including Pfizer, GSK and AstraZeneca. His research has been recognised by awards and Fellowships, most recently the 2019 Sir David Cooksey Translation Prize, the 2020 Corday-Morgan Prize of the RSC, a 2022 Cancer Research UK Programme Award and the 2024 RSC Horizon Prize. In 2023 he was appointed to the GSK Endowed Chair in Chemical Biology at Imperial College. Prof. Tate is also academic founder of several biotechs developing his lab’s research toward clinical applications, including Myricx Bio which in 2024 raised one of the largest Series A rounds to date for a European biotech.
请注意：本次讲座需要生物及化学方向员工签到！
